Source and scope
This summary is bounded to the recommendations, population and decisions covered by Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC vulvovaginitis
Source-attributed clinical priorities
- Confirm typical vulvovaginal symptoms and signs and reconsider bacterial vaginosis, STI, dermatitis and vulvar disease when atypical.
- Use topical or oral azole treatment according to pregnancy, severity, recurrence, interactions and patient preference.
- Culture or arrange specialist assessment for recurrent, complicated or nonresponsive disease rather than repeating empiric therapy indefinitely.
- Recurrent or complicated symptoms should be confirmed microbiologically before repeated antifungal treatment.
sources for this section:SOGC vulvovaginitis
Practical assessment and management workflow
1
Assess itch, soreness, discharge, dysuria, pregnancy, diabetes, antibiotics and immune status.
2
Examine vulva and vagina and use microscopy or culture for atypical, recurrent or resistant disease.
3
Choose topical or oral treatment by severity, pregnancy, species likelihood and interaction risk.
4
Review recurrence for glycemic control, dermatitis, resistant species and alternative diagnoses.
sources for this section:SOGC vulvovaginitis
Safety, red flags and urgent escalation
- Avoid oral fluconazole in pregnancy unless specialist guidance supports a specific circumstance.
- Ulceration, pelvic pain, fever or systemic symptoms are not typical uncomplicated candidiasis.
- Check major drug interactions and liver risk before prolonged oral azole therapy.
sources for this section:SOGC vulvovaginitis
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC vulvovaginitis
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC vulvovaginitis
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Society of Obstetricians and Gynaecologists of CanadaVulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosisaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.